Number of patients with an undetectable VL on current regimen and documented previous NRTI resistance who have switched a PI/r to either an NNRTI or INI as the third agent. Number of patients on PI/r monotherapy as ART maintenance strategy in virologically suppressed patients and record of rationale. Record in patient’s notes of resistance result

at ART initiation (if available) and at first VL >400 copies/mL and/or before switch. Record in patient’s notes of adherence assessment and tolerability/toxicity to ART, in patients experiencing click here virological failure or repeated viral blips. Number of patients experiencing virological failure on current ART regimen. Proportion of patients experiencing virological failure switched to a new suppressive I-BET-762 clinical trial regimen within 6 months. Proportion of patients on ART with previous documented HIV drug resistance with VL <50 copies/mL. Record of patients with three-class virological failure with or without three-class resistance referred/discussed in multidisciplinary team with expert advice. Proportion of patients with TB and CD4 cell count <100 cells/μL started on ART within 2 weeks of starting TB therapy. Proportion of patients with active TB on anti-TB therapy started on ART containing EFV, TDF and FTC. Proportion of patients with a CD4 cell count ≥500 cells/μL and an HBV DNA ≥2000 IU/mL and/or evidence of more than minimal

fibrosis commencing ART inclusive of anti-HBV antivirals. Proportion of patients with a CD4 cell count <500 cells/μL receiving TDF/FTC or TDF/3TC as part of a fully suppressive combination ART regimen. Proportion of patients receiving 3TC or FTC as the sole active drug against HBV in ART. Proportion of patients with a CD4 cell count <500 cells/μL commencing ART. Among patients receiving DAAs for HCV genotype 1 with ART for wild type HIV, the percentage on a recommended regimen,

i.e. RAL with TDF plus FTC with boceprevir; or RAL or boosted ATV with standard dose telaprevir; or EFV with increased dose 1125 mg tds telaprevir. Proportion of patients with an AIDS-defining malignancy on ART. Proportion of patients with a non-AIDS-defining malignancy on ART. Record in patient’s notes of potential pharmacokinetic drug interactions Levetiracetam between ARVs and systemic anticancer therapy. Proportion of patients with symptomatic HIV-associated NC disorders on ART. Proportion of patients with HIV-associated NC disorders on ART containing two NRTIs and one of the following: NNRTI, or PI/r or INI. Proportion of patients with HIVAN started on ART within 2 weeks of diagnosis of CKD. Number of patients with CKD stages 3–5 on ARVs that are potentially nephrotoxic and record of rationale. Record in patient’s notes of the calculated dose of renally cleared ARVs in patients with CKD stage 3 or greater.